Autek China Inc
SZSE:300595
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.27
25.03
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Autek China Inc
Total Equity
Autek China Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Autek China Inc
SZSE:300595
|
Total Equity
ÂĄ4.5B
|
CAGR 3-Years
29%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
||
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Total Equity
ÂĄ23.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
||
Autobio Diagnostics Co Ltd
SSE:603658
|
Total Equity
ÂĄ8.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
||
Winner Medical Co Ltd
SZSE:300888
|
Total Equity
ÂĄ11.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
||
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Total Equity
ÂĄ7.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
Intco Medical Technology Co Ltd
SZSE:300677
|
Total Equity
ÂĄ16.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
Autek China Inc
Glance View
Ovctek China, Inc. engages in the operation of eye vision technology. The company is headquartered in Hefei, Anhui and currently employs 2,772 full-time employees. The company went IPO on 2017-01-17. The firm's main business is non-surgical vision correction. The firm's main products include orthokeratology, general contact lens and care products. Its core product is Dream David orthokeratology. In addition, The Company is also engaged in general glass frame sales business. The firm mainly operates its business in the domestic market.
See Also
What is Autek China Inc's Total Equity?
Total Equity
4.5B
CNY
Based on the financial report for Sep 30, 2024, Autek China Inc's Total Equity amounts to 4.5B CNY.
What is Autek China Inc's Total Equity growth rate?
Total Equity CAGR 5Y
29%
Over the last year, the Total Equity growth was 5%. The average annual Total Equity growth rates for Autek China Inc have been 29% over the past three years , 29% over the past five years .